Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | State-of-the-art CAR-T therapy for B-ALL

Daniel Lee • 8 Jun 2021
EHA 2021
Acute Lymphoblastic Leukemia Leukemia Brexucabtagene autoleucel CAR-T
ZUMA-4

Daniel W. Lee, MD, University of Virginia, Charlottesville, VA, comments on state-of-the-art therapies for B-cell acute lymphoblastic leukemia (B-ALL), highlighting the findings of the ZUMA-4 trial (NCT02625480). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Daniel W. Lee, MD, has participated in a consultancy role for Harpoon Therapeutics; has participated in an external advisory board for Amgen and Juno/Celgene/BMS; has received institutional research funding from Kite Pharma/Gilead; and is the spouse of an employee of Karyopharm Therapeutics.

More from Daniel Lee

2:44
ZUMA-4: 36 month follow-up of brexucabtagene autoleucel for pediatric/adolescent R/R B-ALL
Daniel Lee • 8 Jun 2021
0:55
The management of cytokine release syndrome
Daniel Lee • 8 Jun 2021
8:03
Toxicity issues with CAR T-cell therapy
Bianca Santomasso et al. • 11 Oct 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals